Traders should monitor ZUSDURI's post-J Code sales acceleration in Q1 2026 as a key indicator of commercial traction. While JELMYTO shows stable growth, ZUSDURI's uptake and future guidance will be critical for sentiment. The debt refinancing improves liquidity but adds long-term interest obligations. Pipeline catalysts (UGN-103 NDA in H2 2026, UGN-501 IND by end of 2026) could drive future upside.
Price Chart
Executive Summary
UroGen Pharma reported full-year 2025 financial results with total revenue of $109.8 million, up 21% YoY, driven by the commercial launch of ZUSDURI ($15.8M in sales) and 7% underlying growth in JELMYTO sales ($94M). The company refinanced its debt with Pharmakon Advisors for $200M in non-dilutive capital, strengthening its balance sheet. Despite higher R&D and SG&A expenses, management expressed confidence in ZUSDURI's launch trajectory following the January 2026 effective J Code, and provided 2026 JELMYTO sales guidance of $97M–$101M.
Key Financial Metrics
Key Facts
- ZUSDURI achieved $15.8 million in net sales in 2025, its first full year post-FDA approval (June 2025).
- JELMYTO generated $94.0 million in 2025, reflecting 7% year-over-year underlying demand growth.
- Total revenue increased 21% YoY to $109.8 million in 2025.
- Net loss widened to $153.5 million ($3.19/share) in 2025 from $126.9 million ($2.96/share) in 2024.
- Cash, cash equivalents, and marketable securities declined to $120.5 million as of December 31, 2025, from $241.7 million a year earlier.
- Company secured $200 million refinancing from Pharmakon Advisors, with a $50 million accordion option, at 8.25% fixed interest, repayment starting Q1 2030.
- 2026 JELMYTO sales guidance: $97M–$101M (3–7% growth); no ZUSDURI sales guidance provided.
- 2026 operating expense guidance: $240M–$250M, including $20M–$24M in share-based compensation.
- Phase 3 UTOPIA trial for UGN-103 showed 77.8% three-month complete response rate; NDA planned for H2 2026.
Financial Impact
Revenue grew 21% to $109.8M in 2025, but net loss increased to $153.5M. Operating expenses to remain elevated in 2026 at $240M–$250M. JELMYTO expected to grow modestly by $3M–$7M in 2026.
Risk Factors
- ZUSDURI is in early launch phase with limited sales visibility; reimbursement and adoption may lag expectations.
- Cash position decreased by over 50% YoY to $120.5M, raising potential future financing needs despite new debt.
- Operating losses are widening despite revenue growth, reflecting high commercial and R&D investments.
- Forward-looking statements dominate messaging; actual performance may fall short of management's optimistic tone.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247313 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $45.00 $43.04 | ▼ −4.36% | ▼ −4.02% | $41.40 (−8.00%) |
Aug 20, 2026 6w ago | 8-K | $46.80 $45.50 | ▼ −2.78% | ▼ −3.89% | $41.40 (−11.54%) |
Aug 5, 2026 8w ago | 8-K | $46.43 $49.00 | ▲ +5.54% | ▲ +5.18% | $41.40 (−10.83%) |
Jun 23, 2026 14w ago | 8-K | $35.42 $37.94 | ▲ +7.11% | ▲ +5.41% | $41.40 (+16.88%) |
Jun 2, 2026 17w ago | 8-K | $26.54 $28.18 | ▲ +6.18% | ▲ +9.14% | $41.40 (+55.99%) |
May 6, 2026 21w ago | Press Release | $26.25 $29.80 | ▲ +13.52% | ▲ +12.39% | $41.40 (+57.71%) |
Apr 29, 2026 22w ago | Press Release | $23.34 $23.83 | ▼ −2.10% | ▲ +1.01% | $41.40 (−77.38%) |
Mar 2, 2026 30w ago | Press Release | $19.02 $19.91 | ▲ +4.68% | ▲ +5.89% | $41.40 (+117.67%) |
Mar 2, 2026 30w ago | Press Release | $19.02 $19.91 | ▲ +4.68% | ▲ +5.89% | $41.40 (+117.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access